Summit Therapeutics

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
9926.HK

Recent Articles

RELATED ARTICLES

  1. Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.
    Akeso marks profit milestone with swift rights issue
    9926.HK
  2. Clinical trials come up short again for Alphamab Oncology
    9966.HK
  3. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  4. Sichuan Biokin chases Hong Kong listing after BSM drug deal
  5. Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
    1672.HK
  6. Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva